CrossRef Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives Mario Romeo, Claudio Basile, Andrea Imperatore, Giambattista Mozzi, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio, Alessandro Federico Cells .2026
In early clinical trials, patients on GLP-1 agonists have achieved weight loss of 1520%, compared to the 510% typically seen with previous medications. Holistic approach to GLP-1 drugs Beyond weight loss, GLP-1 agonists have demonstrated the ability to reduce major cardiovascular events, combat fatty liver disease and alleviate obesity-related complications such as knee pain, sleep apnea, and acid reflux
Weeks 5 to 8 (0.5mg dose) First dose increase brings the first significant risk of GI symptoms
C., Physical and Metabolic Characteristics of Persons With Diabetes and Prediabetes, in Diabetes in America (National Institute of Diabetes and Digestive and Kidney Diseases (US), 2018)
A patient currently paying $400-500 per month for brand Entresto could pay $30-50 per month for generic sacubitril/valsartan through a Cost Plus-style pricing model
